Both SEL-110 high dose (HD, 0.15 mg/kg) or low dose (LD, 0.1 mg/kg) with concomitant SEL-037 (0.2 mg/kg), known as SEL-212, demonstrated clinical efficacy and safety among a cohort of patients with gout refractory to standard treatment, according to data presented at the 2024 European Congress of Rheumatology (EULAR). As a lower proportion of patients in the HD group met the stopping rule compared with the LD group, results indicated the higher dose may be more effective.

“In gout refractory to conventional uric acid lowering therapy (ULT), sustained hyperuricemia increases the risk of painful flares, chronic gouty arthropathy, and tophi,” wrote a team of investigators led by Herbert Baraf, MD, clinical professor of Medicine at George Washington University. “Uricase-based therapy can effectively reverse these outcomes but is limited by immunogenicity, which impairs efficacy and compounds the risk of infusion reactions.”

Source: MDMag

To view the third party content, kindly click on the link below or read more. You will then leave this site and enter a third party site.

https://www.hcplive.com/view/sel-212-demonstrates-clinical-safety-efficacy-in-gout